Neoplasms by Site Completed Phase 2 Trials for Dovitinib (DB05928)

IndicationStatusPhase
DBCOND0030096 (Neoplasms by Site)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01576380A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma PatientsTreatment